{"id":"NCT01386528","sponsor":"Novo Nordisk A/S","briefTitle":"Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B","officialTitle":"An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Patients With Haemophilia B","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-07","primaryCompletion":"2013-12-01","completion":"2013-12-01","firstPosted":"2011-07-01","resultsPosted":"2017-07-24","lastUpdate":"2017-08-23"},"enrollment":13,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Congenital Bleeding Disorder","Haemophilia B"],"interventions":[{"type":"DRUG","name":"nonacog beta pegol","otherNames":["NNC-0156-0000-0009"]}],"arms":[{"label":"Patients enrolled in trial","type":"EXPERIMENTAL"}],"summary":"This trial is conducted in Africa, Asia, Europe and the United States of America (USA).\n\nThe aim of the trial is to evaluate the safety and efficacy of NNC-0156-0000-0009 (nonacog beta pegol) during surgical procedures in patients with haemophilia B.","primaryOutcome":{"measure":"Haemostatic Effect During Surgery Evaluated by the Four-point Response Scale (Excellent, Good, Moderate, Poor)","timeFrame":"At the day of surgery","effectByArm":[{"arm":"Nonacog Beta Pegol","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":41,"countries":["United States","Austria","France","Germany","Greece","Italy","Japan","Malaysia","Netherlands","North Macedonia","Romania","South Africa","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Anaemia","Conjunctival haemorrhage","Epigastric discomfort","Excoriation","Face oedema"]}}